Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk
Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into a binding definitive share exchange agreement dated September 5, 2025 (the "SEA") with IDesk Technologies Private Limited ("InterviewDesk"), a private company incorporated under laws of India, and its principal shareholders in respect of an arm's length transaction (the "Transaction") which will change the business of the...
2025-09-08 3:18 PM EDT
Optimind Pharma Announces Termination of Letter of Intent
Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that its previously announced non-binding letter of intent dated March 18, 2025 with Monjin Interviews Private Limited ("Monjin"), with respect to the Company's acquisition of Monjin, has been mutually terminated by the parties.The Company is continuing to evaluate and review alternative acquisition opportunities.About the CompanyThe Company is a reporting...
2025-09-04 4:00 PM EDT
Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the "LOI") to acquire all of the issued and outstanding shares (the "Transaction") of Monjin Interviews Private Limited ("Monjin"), a corporation formed under the laws of India. The Transaction is an arm's length transaction.About Monjin - https://www.monjin.com/Redefining Recruitment...
2025-03-24 11:40 PM EDT
Optimind Pharma Closes Second Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the second trance of its previously announced private placement. The Company issued 2,500,000 common shares at a price of $0.05 per share to investors for gross proceeds of $125,000. The Company expects to close a third tranche of the private placement in the next couple of weeks.Net proceeds will be used for working capital. All securities issued in...
2024-07-29 7:00 AM EDT
Optimind Pharma Closes First Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the first trance of its previously announced private placement. The Company issued 2,900,000 common shares at a price of $0.05 per share to investors for gross proceeds of $145,000.The Company expects to close a second tranche of the private placement in the next couple of weeks.Net proceeds will be used for working capital. All securities issued in...
2024-07-08 4:00 PM EDT
Optimind Pharma - Private Placement
Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces a proposed private placement. The Company intends to issue up to 10,000,000 common shares (the "Shares") at a price of $0.05 per share for gross proceeds of up to $500,000. Net proceeds will be used for working capital. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day...
2024-07-03 4:00 PM EDT
Optimind Pharma Corp. Announces Grant of Options
Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Optimind Pharma Corp. (CSE: OMND) (the "Company") wishes to announce that pursuant to its stock option plan, it has granted stock options to its directors, officers and consultants on March 8, 2023 to purchase up to 5,900,000 common shares of the Company at an exercise price of $0.05 per common share. The options have a term of four (4) years expiring on March 8, 2027. About Optimind Pharma Optimind Pharma is an...
2023-03-10 4:00 PM EST
Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy
Toronto, Ontario--(Newsfile Corp. - September 20, 2022) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") an emerging provider of psychedelic therapies focused on improving the everyday quality of life for individuals who suffer from PTSD, anxiety, depression, and other mental illnesses or disabilities announces today its acquisition of MindSetting Institute, a leader in psychedelic enhanced therapy training and educational programming.The completion of this acquisition...
2022-09-20 8:31 AM EDT
Optimind Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma
Toronto, Ontario--(Newsfile Corp. - August 10, 2022) - Optimind Pharma Corp. (CSE:OMND ("Optimind" or the "Company"), an emerging provider of psychedelic therapies, today provides an update on the Company's joint venture with Manitari Pharma Corporation ("Manitari Pharma"), which is 40% owned by Optimind. Manitari Pharma, which has submitted an application to Health Canada for a Controlled Substances Dealer's License for Psilocybin Research Purposes, has begun the process of permitting and...
2022-08-10 8:31 AM EDT
Optimind Pharma Commences Trading on The CSE Under Ticker Symbol OMND
Toronto, Ontario--(Newsfile Corp. - August 4, 2022) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") today announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol "OMND".Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. Optimind prides itself on providing quality education and health care to patients. Medical cannabis has quickly become one of the most prescribed...
2022-08-04 8:31 AM EDT
Optimind Pharma Announces Closing of Reverse Takeover Transaction
Toronto, Ontario--(Newsfile Corp. - July 29, 2022) - Optimind Pharma Corp. ("Optimind" or the "Company") announces the successful closing of its previously announced reverse takeover ("RTO") of Loon Energy Corporation ("Loon") by Optimind Pharma Inc.In connection with the RTO transaction, a wholly-owned subsidiary of Loon amalgamated with and into Optimind Pharma Inc., and all of the outstanding shares of Optimind Pharma Inc. were exchanged for shares of Loon, and Loon changed its name to...
2022-07-29 8:00 AM EDT